LTA4H and metabolic dysfunction-associated steatohepatitis: Strong evidence ascribes both molecular targets potential in NASH treatment wherein FXR has beneficial effects on hepatic metabolism and lipid homeostasis, and LTA4H is involved in hepatic inflammation and inflammation resolution.